Zenas BioPharma (ZBIO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $24.84, -2.20% vs the prior close of $25.40.
- Volume 661.70K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ZBIO dips 2.2% to $24.84, a 3-month low. Closed at $24.84, -2.20% vs the prior close of $25.40. Day range $24.51–$25.96, opened at $25.36.
ZBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ZBIO dips 2.2% to $24.84, a 3-month low
- Closed at $24.84, -2.20% vs the prior close of $25.40. Day range $24.51–$25.96, opened at $25.36.
- Volume was 661.70K shares, 0.9x its 50-day average of 699.94K.
- Price is -17.6% vs its 50-day average ($30.15) and +0.8% vs its 200-day average ($24.64).
- 52-week range $13.50–$44.60; today's close sits at 36% of that range, 44.3% below the 52-week high.
Oct 15, 2026 — ZBIO rises 2.2% to $25.40
- Closed at $25.40, +2.17% vs the prior close of $24.86. Day range $24.25–$25.94, opened at $24.96.
- Volume was 471.90K shares, 0.7x its 50-day average of 698.73K.
- Price is -16.2% vs its 50-day average ($30.30) and +2.8% vs its 200-day average ($24.70).
- 52-week range $13.50–$44.60; today's close sits at 38% of that range, 43.0% below the 52-week high.
Oct 14, 2026 — ZBIO dips 1.2% to $24.86, a 3-month low, 3 down days in a row
- Closed at $24.86, -1.19% vs the prior close of $25.16. Day range $24.39–$26.49, opened at $24.82.
- Volume was 425.10K shares, 0.6x its 50-day average of 697.79K.
- Price is -18.3% vs its 50-day average ($30.43) and +0.4% vs its 200-day average ($24.77).
- 52-week range $13.50–$44.60; today's close sits at 37% of that range, 44.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ZBIO slides 4.7% to $25.16, a 3-month low
- Closed at $25.16, -4.70% vs the prior close of $26.40. Day range $25.03–$27.00, opened at $26.11.
- Volume was 519.70K shares, 0.7x its 50-day average of 695.98K.
- Price is -17.7% vs its 50-day average ($30.56) and +1.2% vs its 200-day average ($24.85).
- 52-week range $13.50–$44.60; today's close sits at 37% of that range, 43.6% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — ZBIO slides 3.2% to $26.40
- Closed at $26.40, -3.15% vs the prior close of $27.26. Day range $26.30–$27.49, opened at $26.93.
- Volume was 602.50K shares, 0.9x its 50-day average of 692.97K.
- Price is -13.9% vs its 50-day average ($30.68) and +5.8% vs its 200-day average ($24.94).
- 52-week range $13.50–$44.60; today's close sits at 41% of that range, 40.8% below the 52-week high.
Oct 9, 2026 — ZBIO jumps 3.9% to $27.26
- Closed at $27.26, +3.89% vs the prior close of $26.24. Day range $26.18–$27.64, opened at $26.18.
- Volume was 429.60K shares, 0.6x its 50-day average of 699.14K.
- Price is -11.4% vs its 50-day average ($30.78) and +8.9% vs its 200-day average ($25.03).
- 52-week range $13.50–$44.60; today's close sits at 44% of that range, 38.9% below the 52-week high.
Oct 8, 2026 — ZBIO slides 6.9% to $26.24, a 3-month low
- Closed at $26.24, -6.88% vs the prior close of $28.18. Day range $25.51–$27.98, opened at $27.98.
- Volume was 557.50K shares, 0.8x its 50-day average of 700.50K.
- Price is -15.0% vs its 50-day average ($30.88) and +4.5% vs its 200-day average ($25.10).
- 52-week range $13.50–$44.60; today's close sits at 41% of that range, 41.2% below the 52-week high.
Oct 7, 2026 — ZBIO jumps 4.6% to $28.18
- Closed at $28.18, +4.60% vs the prior close of $26.94. Day range $26.77–$28.86, opened at $26.89.
- Volume was 509.10K shares, 0.7x its 50-day average of 705.80K.
- Price is -9.0% vs its 50-day average ($30.97) and +12.0% vs its 200-day average ($25.15).
- 52-week range $13.50–$44.60; today's close sits at 47% of that range, 36.8% below the 52-week high.
Oct 6, 2026 — ZBIO slides 3.2% to $26.94
- Closed at $26.94, -3.20% vs the prior close of $27.83. Day range $26.28–$28.14, opened at $27.87.
- Volume was 357.60K shares, 0.5x its 50-day average of 721.72K — lighter than usual.
- Price is -13.3% vs its 50-day average ($31.06) and +7.0% vs its 200-day average ($25.19).
- 52-week range $13.50–$44.60; today's close sits at 43% of that range, 39.6% below the 52-week high.
Oct 5, 2026 — ZBIO dips 1.6% to $27.83
- Closed at $27.83, -1.64% vs the prior close of $28.30. Day range $27.77–$29.06, opened at $28.47.
- Volume was 1.13M shares, 1.6x its 50-day average of 710.26K.
- Price is -10.7% vs its 50-day average ($31.17) and +10.3% vs its 200-day average ($25.23).
- 52-week range $13.50–$44.60; today's close sits at 46% of that range, 37.6% below the 52-week high.
Oct 2, 2026 — ZBIO rises 1.3% to $28.30 on 2.2x normal volume
- Closed at $28.30, +1.27% vs the prior close of $27.94. Day range $27.84–$29.20, opened at $28.47.
- Volume was 1.51M shares, 2.2x its 50-day average of 688.03K — unusually heavy trading.
- Price is -9.4% vs its 50-day average ($31.23) and +11.9% vs its 200-day average ($25.28).
- 52-week range $13.50–$44.60; today's close sits at 48% of that range, 36.6% below the 52-week high.
- That makes 3 straight gains.
ZBIO latest news & SEC filings
Every SEC filing by or about ZBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 11, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 11, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 8, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 8, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 19, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 19, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 17, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.00M
- Net income: -$111.46M (prior year -$52.22M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.77 (prior year -$1.25) (loss widened vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade ZBIO
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 16, 2026, Jan 5, 2026. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.44% (largest 10.3%). That is a volatile stock.
- Liquidity: about 642.22K shares (≈$15.95M) trade per day on average.
- 52-week position: $24.84 vs a range of $13.50–$44.60 (36% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Leon O Jr Moulder bought 60,000 shares on May 18, 2026.
- Latest filings: 8-K Oct 13, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Share count: 65.18M shares outstanding (Jul 31, 2026), +54.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ZBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 25.36 | 25.96 | 24.51 | 24.84 | 661.70K |
| Oct 15, 2026 | 24.96 | 25.94 | 24.25 | 25.40 | 471.90K |
| Oct 14, 2026 | 24.82 | 26.49 | 24.39 | 24.86 | 425.10K |
| Oct 13, 2026 | 26.11 | 27.00 | 25.03 | 25.16 | 519.70K |
| Oct 12, 2026 | 26.93 | 27.49 | 26.30 | 26.40 | 602.50K |
| Oct 9, 2026 | 26.18 | 27.64 | 26.18 | 27.26 | 429.60K |
| Oct 8, 2026 | 27.98 | 27.98 | 25.51 | 26.24 | 557.50K |
| Oct 7, 2026 | 26.89 | 28.86 | 26.77 | 28.18 | 509.10K |
| Oct 6, 2026 | 27.87 | 28.14 | 26.28 | 26.94 | 357.60K |
| Oct 5, 2026 | 28.47 | 29.06 | 27.77 | 27.83 | 1.13M |
| Oct 2, 2026 | 28.47 | 29.20 | 27.84 | 28.30 | 1.51M |
| Oct 1, 2026 | 26.89 | 29.23 | 26.55 | 27.94 | 881.90K |
| Sep 30, 2026 | 26.99 | 28.38 | 26.54 | 26.97 | 623.20K |
| Sep 29, 2026 | 27.30 | 27.61 | 26.18 | 26.76 | 440.60K |
| Sep 28, 2026 | 27.07 | 28.23 | 26.45 | 27.55 | 615.30K |
| Sep 25, 2026 | 27.44 | 28.50 | 25.90 | 26.95 | 747.80K |
| Sep 24, 2026 | 29.51 | 30.12 | 25.70 | 27.50 | 962.90K |
| Sep 23, 2026 | 33.09 | 33.09 | 29.53 | 29.63 | 525.10K |
| Sep 22, 2026 | 32.55 | 33.84 | 32.15 | 33.05 | 452.80K |
| Sep 21, 2026 | 31.62 | 33.19 | 31.00 | 32.55 | 414.50K |
About Zenas BioPharma
Zenas BioPharma (ZBIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1953926.
ZBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Patricia L Allen | Director | Jun 17, 2026 |
| James P Boylan | Director | Jun 17, 2026 |
| Patrick G Enright | Director | Jun 17, 2026 |
| Funds Management Llc Fairmount | Director | Apr 1, 2026 |
| Healthcare Fund Ii L.P. Fairmount | Director | Apr 1, 2026 |
| Peter Evan Harwin | Director | Apr 1, 2026 |
| Tomas Kiselak | Director | Apr 1, 2026 |
| Hongbo Lu | Director | Jun 17, 2026 |
| Leon O Jr Moulder | See Remarks | Jun 17, 2026 |
| Jason Raleigh Nunn | Director | Jun 17, 2026 |
| John J Orloff | Director | Jun 17, 2026 |
| Christy J. Oliger | Director | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Joseph L Farmer | See Remarks | Jun 17, 2026 |
| Jennifer A. Fox | See Remarks | Jun 17, 2026 |
| Leon O Jr Moulder | See Remarks | Jun 17, 2026 |
| Moltke Lisa Von | See Remarks | Jun 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 18, 2026 | Leon O Jr Moulder | Buy | 60,000 | $16.88 |
| May 18, 2026 | Leon O Jr Moulder | Buy | 60,000 | $16.88 |
| May 18, 2026 | Leon O Jr Moulder | Buy | 60,000 | $16.88 |
| May 18, 2026 | Leon O Jr Moulder | Buy | 60,000 | $16.88 |
| Apr 29, 2026 | Leon O Jr Moulder | Buy | 35,000 | $17.62 |
| Apr 29, 2026 | Leon O Jr Moulder | Buy | 35,000 | $17.62 |
| Apr 29, 2026 | Leon O Jr Moulder | Buy | 35,000 | $17.62 |
| Apr 29, 2026 | Leon O Jr Moulder | Buy | 35,000 | $17.62 |
| Apr 28, 2026 | Leon O Jr Moulder | Buy | 25,000 | $18.02 |
| Apr 28, 2026 | Leon O Jr Moulder | Buy | 25,000 | $18.02 |
| Apr 28, 2026 | Leon O Jr Moulder | Buy | 25,000 | $18.02 |
| Apr 28, 2026 | Leon O Jr Moulder | Buy | 25,000 | $18.02 |
| Mar 31, 2026 | Leon O Jr Moulder | Buy | 34,000 | $19.31 |
| Mar 31, 2026 | Leon O Jr Moulder | Buy | 34,000 | $19.31 |
| Mar 31, 2026 | Leon O Jr Moulder | Buy | 34,000 | $19.31 |
ZBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $10.00M | $-377.74M | -8.44 | $-172.33M |
| Dec 31, 2024 | $5.00M | $-156.99M | -11.89 | $-119.67M |
| Dec 31, 2023 | $50.00M | $-37.12M | -24.25 | $-30.53M |
Latest balance sheet: total assets $701.69M, total liabilities $454.59M, cash $196.58M (as of Jun 30, 2026).
ZBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $29.20 |
| May 13, 2026 | 8-K Item 2.02 (results) | $19.93 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $23.23 |
| Jan 5, 2026 | 8-K Item 2.02 (results) | $16.61 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $35.80 |
| Oct 8, 2025 | 8-K Item 2.02 (results) | $25.90 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $15.90 |
| May 15, 2025 | 8-K Item 2.02 (results) | $9.74 |
| Feb 5, 2025 | 8-K Item 2.02 (results) | $7.92 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $20.61 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ZBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.